Yes, we could get revenue in 2023 as reimbursement for the TAVR’s used in the trials but it will be very modest. But much better than no revenue and having to fund the cost of the valves. So it’s a positive.
Dr Poon becomes the first Aussie Dr to use DurAVR., page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.85 |
Change
-0.150(3.00%) |
Mkt cap ! $75.19M | |||
| Open | High | Low | Value | Volume |
| $5.00 | $5.00 | $4.84 | $15.32K | 3.146K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 882 | $4.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.20 | 2136 | 2 |
View Market Depth
| Last trade - 15.14pm 25/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |